Wang HY, Pei Z, Lee KC, Lopez-Brignoni E, Nikolov B, Crowley CA, Marsman MR, Barbier R, Friedmann N, Burns LH. PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients. J Prev Alzheimers Dis. 2020;7(4):256-264. PubMed.
Recommends
Please login to recommend the paper.
Comments
Medical University of South Carolina
While interesting, the reason baseline and post-treatment CSF Aβ42 levels are so low in the analysis needs to be explained. See Kokkinou et al., 2021. How does Simufilam differ from LSD in structure?
References:
Kokkinou M, Beishon LC, Smailagic N, Noel-Storr AH, Hyde C, Ukoumunne O, Worrall RE, Hayen A, Desai M, Ashok AH, Paul EJ, Georgopoulou A, Casoli T, Quinn TJ, Ritchie CW. Plasma and cerebrospinal fluid ABeta42 for the differential diagnosis of Alzheimer's disease dementia in participants diagnosed with any dementia subtype in a specialist care setting. Cochrane Database Syst Rev. 2021 Feb 10;2:CD010945. PubMed.
Cassava Sciences, Inc.
Thanks for your comment. Aβ42 was measured using Invitrogen's ELISA kit. Different antibodies can produce very different results, even though all translate data to pg/mL. I can say that the R2 values for the standard curves for all ELISAs were 0.88 or higher. I cannot access this full paper—which ELISA plates were used? Simufilam is not LSD. That was plugged into a presentation once when we were not yet disclosing structure.
Make a Comment
To make a comment you must login or register.